Regimen-Dependent Anti-Cytokine and Immune-Checkpoint Autoantibodies Are Associated with Immunotherapy Toxicity and Response in Melanoma
International Journal of Molecular Sciences · 30.10.2026 · 27 (21) · 9746
DOI: 10.3390/ijms27219746 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 30.10.2026. Verfasst von Robin Reschke und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Heidelberg and National Center for Tumor Diseases (NCT), NCT Heidelberg, a Partnership Between DKFZ an…. Hauptthemen laut MEDLINE: Melanoma, Cytokines, Autoantibodies, Immunotherapy. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alden Scientific Immune GmbH, German Cancer Aid, Else Kroener-Fresenius Foundation.
Abstract (Originalsprache)
Immune checkpoint inhibitor (ICI) efficacy and immune-related adverse events (irAEs) in melanoma are influenced by the pre-treatment immune state. We investigated whether baseline autoantibodies directed against cytokines, chemokines, cytokine receptors, and immune-checkpoint/costimulatory proteins were associated with outcome in a regimen-dependent manner. Baseline sera from patients with metastatic melanoma were profiled on a multiplex bead array of 86 cytokine, chemokine, cytokine-receptor and immune-checkpoint antigens, and associations with best overall response and irAE development were assessed within pre-specified treatment strata by label-permutation testing with Benjamini–Hochberg false-discovery-rate control (SAM as a sensitivity analysis). Associations differed by ICI regimen. Anti-IL17A and anti-CCL2 reactivity was higher in patients developing irAEs under ipilimumab monotherapy (both p = 0.003) and shifted in the opposite direction under pembrolizumab without prior CTLA-4 therapy. Higher anti-PD-L1/CD274 and anti-CCL5 and lower anti-KIT reactivity were associated with response to pembrolizumab without prior CTLA-4 therapy (p = 0.025, p = 0.002, p = 0.006), and lower anti-MCAM and anti-CSF3 reactivity with response under ipilimumab/nivolumab (p = 0.001 and p = 0.002). No association survived false-discovery-rate correction, so all findings are exploratory and hypothesis-generating; higher baseline anti-IL10 reactivity was a leading irAE signal under pembrolizumab without prior CTLA-4 therapy (p = 0.027). These regimen-dependent humoral markers warrant prospective, regimen-stratified validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University Hospital Heidelberg and National Center for Tumor Diseases (NCT), NCT Heidelberg, a Partnership Between DKFZ and University Hospital Heidelberg, 69120 Heidelberg, Germany.
- German Cancer Consortium (DKTK), Core Center DKFZ Heidelberg, 69120 Heidelberg, Germany.
- Medical Faculty, University Heidelberg, 69120 Heidelberg, Germany.
- German Cancer Research Center (DKFZ), Applied Tumor Immunity, 69120 Heidelberg, Germany.
- Alden Scientific Immune GmbH, 44227 Dortmund, Germany.
- Department of Dermatology, University Hospital Zürich, 8091 Zürich, Switzerland.
ORCID-Profile: Robin Reschke, Petra Budde, Reinhard Dummer, Claudia Pföhler, Jessica C Hassel
Förderung
- Alden Scientific Immune GmbH
- German Cancer Aid
- Else Kroener-Fresenius Foundation
Zitieren
APA
Reschke, R., Zucht, H. D., Budde, P., Mangana, J., Dummer, R., Pföhler, C., Wistuba-Hamprecht, K., Weide, B., Meier, F., Hakim-Meibodi, L. E., Schulz, C., Richter, J., Enk, A. H., Bräutigam, M., Nguyen, T. N. M., & Hassel, J. C. (2026). Regimen-Dependent Anti-Cytokine and Immune-Checkpoint Autoantibodies Are Associated with Immunotherapy Toxicity and Response in Melanoma. International Journal of Molecular Sciences, 27(21), 9746. https://doi.org/10.3390/ijms27219746
Vancouver
Reschke R, Zucht HD, Budde P, Mangana J, Dummer R, Pföhler C, et al. Regimen-Dependent Anti-Cytokine and Immune-Checkpoint Autoantibodies Are Associated with Immunotherapy Toxicity and Response in Melanoma. International Journal of Molecular Sciences. 2026;27(21):9746. doi:10.3390/ijms27219746
BibTeX
@article{Reschke2026,
author = {Reschke, Robin and Zucht, Hans-Dieter and Budde, Petra and Mangana, Joanna and Dummer, Reinhard and Pföhler, Claudia and Wistuba-Hamprecht, Kilian and Weide, Benjamin and Meier, Friedegund and Hakim-Meibodi, Lara-Elena and Schulz, Carsten and Richter, Jasmin and Enk, Alexander H and Bräutigam, Manuel and Nguyen, Thi Nhat Minh and Hassel, Jessica C},
title = {Regimen-Dependent Anti-Cytokine and Immune-Checkpoint Autoantibodies Are Associated with Immunotherapy Toxicity and Response in Melanoma},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {21},
pages = {9746},
doi = {10.3390/ijms27219746}
}
EUVIMED